Juvenescence

LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD).

Morphoceuticals is a biotechnology platform establishing a basis for limb regeneration and the discovery of regenerative interventions. It focuses on the understanding of the biophysical mechanisms that implement decision-making during complex pattern regulation and utilizes bioelectric dynamics to change developmental patterning and spur regeneration in organisms that do not regenerate tissues or organs. It helps medical researchers to treat complicated health states through limb regeneration, improving amputation stump health, promoting organ regeneration, and the treatment of channelopathies.

MDI Therapeutics is a discovery stage pharmaceutical company focused on developing innovative therapies for fibrotic diseases and fibroproliferative disorders. The company utilizes a proprietary discovery platform to identify novel small molecule and protein drug candidates. These candidates undergo key translational experiments involving clinical biomarkers to assess their effectiveness. MDI Therapeutics aims to enable healthcare providers to prevent fibrosis and potentially reverse the fibrotic disease process, addressing significant unmet medical needs in this area.

Portage Pharmaceuticals LTD. is developing innovative cell permeable peptide (CPP) therapies to normalize gene expression, restore protein function, and improve medical outcomes. The Company has spun out its lead asset, PPL-003, to ophthalmic indications and has licensed this CellPorter technology to EyGen, a new ophthalmic company.

LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD).

LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD).

Souvien Therapeutics is a biotechnology company focused on developing therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration.

BYOMass is developing therapeutics to modulate the central control of metabolism associated with aging and age-related chronic illnesses.

BHB Therapeutics is developing novel approaches to induce a state of ketosis, which may have protective effects against age-related disease.

AgeX Therapeutics is a biotechnology company dedicated to developing innovative therapeutics aimed at addressing human aging and degenerative diseases. Based in Alameda, California, the company focuses on harnessing proprietary technologies, such as telomerase-mediated cell immortality and induced Tissue Regeneration (iTR), to create treatments for age-related conditions. Its primary product pipeline includes two cell-based therapies: AGEX-BAT1, designed to treat age-related metabolic disorders like Type II diabetes, and AGEX-VASC1, which aims to restore vascular support in ischemic tissues. Additionally, AgeX is advancing AGEX-iTR1547, a drug-based formulation intended to enhance regenerative potential in aged tissues affected by degenerative diseases. The company also markets human embryonic stem cells and offers tools for genomic interpretation through the GeneCards Database Suite. AgeX Therapeutics collaborates with academic institutions, including a research program with the University of California, Irvine, focusing on neural stem cells for Huntington's disease and other neurological disorders. Founded in 2017, AgeX continues to explore novel solutions for aging-related challenges.

Napa Therapeutics is a biotechnology company focused on a novel target linked to one of the fundamental processes of aging. A privately held British Virgin Islands company with an office in the Isle of Man, Napa is developing small molecule drugs to address this target.

FoxBio is a developer of a small molecules techniques intended to reduce senescent cells in human bodies. The company's techniques targets the pro-survival pathways of senescent cells to remove them from the body, enabling patients to have multiple health benefits and delay the onset of age related diseases.

Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.

AgeX Therapeutics is a biotechnology company dedicated to developing innovative therapeutics aimed at addressing human aging and degenerative diseases. Based in Alameda, California, the company focuses on harnessing proprietary technologies, such as telomerase-mediated cell immortality and induced Tissue Regeneration (iTR), to create treatments for age-related conditions. Its primary product pipeline includes two cell-based therapies: AGEX-BAT1, designed to treat age-related metabolic disorders like Type II diabetes, and AGEX-VASC1, which aims to restore vascular support in ischemic tissues. Additionally, AgeX is advancing AGEX-iTR1547, a drug-based formulation intended to enhance regenerative potential in aged tissues affected by degenerative diseases. The company also markets human embryonic stem cells and offers tools for genomic interpretation through the GeneCards Database Suite. AgeX Therapeutics collaborates with academic institutions, including a research program with the University of California, Irvine, focusing on neural stem cells for Huntington's disease and other neurological disorders. Founded in 2017, AgeX continues to explore novel solutions for aging-related challenges.

LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD).